Pharma Market Access Insights - from Mtech Access

64 Episodes

1. Navigating US payer evidence needs to optimise market access

   Published: 11/27/2024
2. Best practice RWE approaches to support economic modelling for HTA

   Published: 11/20/2024
3. NHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to Christmas

   Published: 11/18/2024
4. De-mystifying the NHS – What you need to know about the NHS as a market for your health technology

   Published: 10/11/2024
5. NHS primary care panel – the GP Contract and Operational Planning Guidance

   Published: 9/10/2024
6. Engage NHS healthcare decision-makers with RWD

   Published: 8/12/2024
7. Market access and reimbursement in Canada – changes at CADTH

   Published: 6/20/2024
8. Rare Disease market access in the MENA and Nordic regions

   Published: 5/10/2024
9. How does funding flow in NHSE Regions?

   Published: 4/9/2024
10. NHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)

    Published: 4/9/2024
11. De-mystifying health economic model classifications and structures

    Published: 3/22/2024
12. Evidence strategy for Medical Technologies and Diagnostics

    Published: 3/12/2024
13. How to set your Pharma or Medtech product up for success in the US market

    Published: 2/26/2024
14. What's happening with specialised commissioning in the NHS?

    Published: 2/12/2024
15. Integrated care in NHS Wales – what can England learn from its neighbour?

    Published: 1/17/2024
16. Market access in Italy: Reforms at AIFA

    Published: 12/18/2023
17. Unmet need in NHS primary care – How can industry best support PCN leaders?

    Published: 11/28/2023
18. Population health management: a community effort across health and life sciences

    Published: 11/1/2023
19. Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

    Published: 10/26/2023
20. 6 areas of UK health policy for Medtech to pay attention to

    Published: 10/16/2023